News about PARP inhibitors for triple-negative cancers?


Question from MomOf4: Any new news this year about PARP inhibitors for triple-negative?
Answers - Andrew D. Seidman, M.D. While we still await the data from a large randomized Phase III trial evaluating BSI-201, there were several smaller studies reported at this year's ASCO meeting. One study involved the oral PARP inhibitor olaparib, which was administered with weekly Taxol (chemical name: paclitaxel) chemotherapy for triple-negative metastatic breast cancer. (Abstract number 1018 at ASCO.) Another study examined yet another PARP inhibitor, veliparib, in combination with a chemotherapy agent called Temodar (chemical name: temozolomide). In this trial, significant responses were seen in patients with metastatic breast cancer who carried BRCA mutations. Still, to date there are no commercially available PARP inhibitors, and their ultimate role depends upon the awaited results of large randomized trials.

On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this resource helpful?

Yes No
Evergreen-donate
Back to Top